Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer

Bibliography

• Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20(11):1771–85
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13(10):714–26
   PubMed Web of Science ®Google Scholar
• Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55(11):2325–33
   PubMed Web of Science ®Google Scholar
• Gerth K, Bedorf N, Hofle G, et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot 1996;49(6):560–3
   PubMed Web of Science ®Google Scholar
• Altmann KH. Recent developments in the chemical biology of epothilones. Curr Pharm Des 2005;11(13):1595–613
   PubMed Web of Science ®Google Scholar
• Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008;13(12):1207–23
   PubMed Web of Science ®Google Scholar
• Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010;10(3):194–204
   PubMed Web of Science ®Google Scholar
• Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 2004;305(5685):866–9
   PubMed Web of Science ®Google Scholar
• Bode CJ, Gupta MLJr, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002;41(12):3870–4
   PubMed Web of Science ®Google Scholar
• Rojas-Espaillat L, Uyar D, Grabowski D, et al. Apoptotic pathways induced by ixabepilone in paclitaxel-refractory ovarian carcinoma cells. Proc Am Assoc Cancer Res 2005;46:abstract 5318
   Google Scholar
• Yamaguchi H, Chen J, Bhalla K, et al. Regulation of Bax activation and apoptotic response to microtubule-damaging agents by p53 transcription-dependent and -independent pathways. J Biol Chem 2004;279(38):39431–7
   PubMed Web of Science ®Google Scholar
• Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009;63(2):201–12
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009;8(1):17–25
   PubMed Web of Science ®Google Scholar
• Yardley DA. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 2008;8(6):487–92
   PubMed Web of Science ®Google Scholar
• Lee F, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 2006;24(Suppl):abstract 12017
   Google Scholar
• Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 2011;3(1):11–25
   PubMedGoogle Scholar
• Lee F, Castaneda S, Inigo I, et al. Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers. J Clin Oncol 2005;23(Suppl):abstract 561
   Google Scholar
• Mainwaring P, Nguyen T, Price G, et al. Ixabepilone and lapatinib for HER2-positive advanced breast cancer: Preclinical rationale and phase I trial. J Clin Oncol 2009;27(Suppl):abstract 2582
   Google Scholar
• Lee FY, Covello KL, Castaneda S, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 2008;14(24):8123–31
   PubMed Web of Science ®Google Scholar
• Jure-Kunkel M, Masters G, Girit E, et al. Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. Cancer Immunol Immunother 2013;62(9):1533–45
   PubMed Web of Science ®Google Scholar
• Bush TL, Payton M, Heller S, et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol Cancer Ther 2013;12(11):2356–66
   PubMed Web of Science ®Google Scholar
• Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10(4):1289–98
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11(17):6233–9
   PubMed Web of Science ®Google Scholar
• Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21(9):1866–73
   PubMed Web of Science ®Google Scholar
• Zhuang SH, Agrawal M, Edgerly M, et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103(9):1932–8
   PubMed Web of Science ®Google Scholar
• Awada A, Piccart MJ, Jones SF, et al. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol 2009;63(3):417–25
   PubMed Web of Science ®Google Scholar
• Kunz PL, He AR, Colevas AD, et al. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Invest New Drugs 2012;30(6):2364–70
   PubMed Web of Science ®Google Scholar
• Deeken JF, Marshall JL, Pishvaian MJ, et al. A phase I study of oral ixabepilone in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014;73(5):1071–8
   PubMed Web of Science ®Google Scholar
• Goel S, Cohen M, Comezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 2008;14(9):2701–9
   PubMed Web of Science ®Google Scholar
• Ixempra. US Food and Drug Administration. Prescribing Information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022065s002lbl.pdf [Last accessed March 2015]
   Google Scholar
• Comezoglu SN, Ly VT, Zhang D, et al. Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metab Pharmacokinet 2009;24(6):511–22
   PubMed Web of Science ®Google Scholar
• Takimoto C, Liu P, Lenz H, et al. A phase I pharmacokinetic (PK) study of the Epothilone B analogue, ixabepilone (BMS-247550) in patients (pts) with advanced malignancies and varying degrees of hepatic impairment. A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial. J Clin Oncol 2006;24(Suppl):abstract 2004
   Google Scholar
• Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25(23):3407–14
   PubMed Web of Science ®Google Scholar
• Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25(23):3399–406
   PubMed Web of Science ®Google Scholar
• Roche H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25(23):3415–20
   PubMed Web of Science ®Google Scholar
• Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23(12):2726–34
   PubMed Web of Science ®Google Scholar
• Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25(23):3421–7
   PubMed Web of Science ®Google Scholar
• Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008;8(3):234–41
   PubMed Web of Science ®Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25(33):5210–17
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Gomez HL, Li RK, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010;122(2):409–18
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28(20):3256–63
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363(20):1938–48
   PubMed Web of Science ®Google Scholar
• Rugo H, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies. Cancer Res 2009;69:abstract 3057
   Google Scholar
• Moulder S, Li H, Wang M, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 2010;119(3):663–71
   PubMed Web of Science ®Google Scholar
• Tolaney SM, Najita J, Sperinde J, et al. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2013;24(7):1841–7
   PubMed Web of Science ®Google Scholar
• ClinicalTrialsgov Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer. Available from: https://clinicaltrialsgov/ct2/show/NCT00634088
   Google Scholar
• Rugo HS, Campone M, Amadori D, et al. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 2013;139(2):411–19
   PubMed Web of Science ®Google Scholar
• Rugo H, Barry W, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012;30(Suppl):abstract CRA1002
   Google Scholar
• Tredan O, Campone M, Jassem J, et al. Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. Clin Breast Cancer 2015;15(1):8–15
   PubMed Web of Science ®Google Scholar
• Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009;27(4):526–34
   PubMed Web of Science ®Google Scholar
• Zubkus J, Daniel D, Eakle J, et al. Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial. J Clin Oncol 2011;29(Suppl):abstract 621
   Google Scholar
• Rodriguez A, Salazar N, Patel T, et al. A randomized, parallel-arm, phase II trial to assess the efficacy of preoperative ixabepilone with or without cetuximab in patients with triple-negative breast cancer (TNBC). J Clin Oncol 2014;32(Suppl):abstract 1133
   Google Scholar
• Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42
   PubMed Web of Science ®Google Scholar
• Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015;75(4):659–70
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Lara PNJr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007;25(23):3448–55
   PubMed Web of Science ®Google Scholar
• Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010;121(2):261–71
   PubMed Web of Science ®Google Scholar
• Horak CE, Pusztai L, Xing G, et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res 2013;19(6):1587–95
   PubMed Web of Science ®Google Scholar